γ-Hydroxybutyrate/sodium oxybate: Neurobiology, and impact on sleep and wakefulness

CNS Drugs

Volumn 20, Issue 12, 2006, Pages 993-1018

  Pardi, Daniel ^a   Black, Jed ^b  

^a JAZZ PHARMACEUTICALS   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BUTANEDIOL; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 HYDROXYBUTYRIC ACID; AMPHETAMINE; BACLOFEN; BARBITURIC ACID DERIVATIVE; DEXAMPHETAMINE; ETHOSUXIMIDE; FLUMAZENIL; GAMMA BUTYROLACTONE; GAMMA HYDROXYVALERATE; GAMMA VALEROLACTONE; GROWTH HORMONE; METERGOLINE; METHYLPHENIDATE; MODAFINIL; NALOXONE; NEUROSTEROID; NEUROTRANSMITTER; OXYBATE SODIUM; PENTOBARBITAL; PIRENZEPINE; PLACEBO; SULPIRIDE; TRIAZOLAM; VALERIC ACID DERIVATIVE; VALPROIC ACID;

CATAPLEXY; CHOLINERGIC SYSTEM; CITRIC ACID CYCLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DAYTIME SOMNOLENCE; DIZZINESS; DOPAMINERGIC SYSTEM; DRUG ABSORPTION; DRUG ABUSE; DRUG BINDING; DRUG BINDING SITE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG WITHDRAWAL; FATIGUE; FIBROMYALGIA; HEADACHE; HUMAN; IC 50; INSOMNIA; LOW DRUG DOSE; MEMORY DISORDER; MONOTHERAPY; NARCOLEPSY; NAUSEA; NERVE CELL; NEUROBIOLOGY; NEUROMODULATION; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NIGHT SLEEP; NONHUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEDATION; SEROTONINERGIC SYSTEM; SIDE EFFECT; SLEEP; SLEEP TIME; SLEEP WAKING CYCLE; SOMNOLENCE; TACHYPHYLAXIS; WAKEFULNESS; WITHDRAWAL SYNDROME;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; NEUROBIOLOGY; SLEEP; SODIUM OXYBATE; WAKEFULNESS;

EID: 33845479670     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: 10.2165/00023210-200620120-00004     Document Type: Review

References (221)

1. Bessman SP, Fishbein WN. Gamma-hydroxybutyrate, a normal brain metabolite. Nature 1963 Dec 21; 200: 1207-8
2. Roth RH, Giarman NJ. Conversion in vivo of gamma-aminobutyric to gamma-hydroxybutyric acid in the rat. Biochem Pharmacol 1969 Jan; 18 (1): 247-50
3. Fishbein WN, Bessman SP. Gamma-hydroxybutyrate in mammalian brain: reversible oxidation by lactic dehydrogenase. J Biol Chem 1964 Jan; 239: 357-61
4. Doherty JD, Hattox SE, Snead OC, et al. Identification of endogenous gamma-hydroxybutyrate in human and bovine brain and its regional distribution in human, guinea pig and rhesus monkey brain. J Pharmacol Exp Ther 1978 Oct; 207 (1): 130-9
5. Snead III OC, Furner R, Liu CC. In vivo conversion of gamma-aminobutyric acid and 1,4-butanediol to gamma-hydroxybutyric acid in rat brain: studies using stable isotopes. Biochem Pharmacol 1989 Dec 15; 38 (24): 4375-80
6. Laborit H. Sodium 4-hydroxybutyrate. Int J Neuropharmacol 1964 Sep; 32: 433-51
7. Helrich M, McAslan TC, Skolnik S, et al. Correlation of blood levels of 4-hydroxybutyrate with state of consciousness. Anesthesiology 1964 Nov-Dec; 25: 771-5
8. Blumenfeld M, Suntay RG, Harmel MH. Sodium gamma-hydroxybutyric acid: a new anaesthetic adjuvant. Anesth Analg 1962; 41: 721-6
9. Laborit G, Larcan A, Kind A. Electrocardiographic study of sodium 4-hydroxybutyrate [in French]. Agressologie 1963 Jan-Feb; 4: 77-88
10. Solway J, Sadove MS. 4-Hydroxybutyrate: a clinical study. Anesth Analg 1965 Sep-Oct; 44 (5): 532-9
11. Kleinschmidt S, Schellhase C, Mertzlufft F. Continuous sedation during spinal anaesthesia: gamma-hydroxybutyrate vs. propofol. Eur J Anaesthesiol 1999 Jan; 16 (1): 23-30
12. Kleinschmidt S, Grundmann U, Knocke T, et al. Total intravenous anaesthesia with gamma-hydroxybutyrate (GHB) and sufentanil in patients undergoing coronary artery bypass graft surgery: a comparison in patients with unimpaired and impaired left ventricular function. Eur J Anaesthesiol 1998 Sep; 15 (5): 559-64
13. Metcalf DR, Emde RN, Stripe JT. An EEG-behavioral study of sodium hydroxybutyrate in humans. Electroencephalogr Clin Neurophysiol 1966 May; 20 (5): 506-12
14. Yamada Y, Yamamoto J, Fujiki A, et al. Effect of butyrolactone and gamma-hydroxybutyrate on the EEG and sleep cycle in man. Electroencephalogr Clin Neurophysiol 1967 Jun; 22 (6): 558-62
15. Strong AJ. Gamma-hydroxybutyric acid and intracranial pressure [letter]. Lancet 1984 Jun 9; 1 (8389): 1304
16. Miller JD, Piper IR, Dearden NM. Management of intracranial hypertension in head injury: matching treatment with cause. Acta Neurochir Suppl (Wien). 1993; 57: 152-9
17. Kolin A, Brezina A, Mamelak M, et al. Cardioprotective action of sodium gamma-hydroxybutyrate against isoproterenol induced myocardial damage. Int J Exp Pathol 1993 Jun; 74 (3): 275-81
18. Laborit G, Baron C, Topal G, et al. Value of sodium gamma hydroxybutyrate in cerebral protection during severe hypoxia in the rat [in French]. Agressologie 1980; 21 (4): 189-97
19. Artru AA, Steen PA, Michenfelder JD. Gamma-hydroxybutyrate: cerebral metabolic, vascular, and protective effects. J Neurochem 1980 Nov; 35 (5): 1114-9
20. Malyshev VV, Treshchuk LI, Belykh NG. Evaluation of the protective effect of gamma-hydroxybutyric acid in stress [in Russian]. Biull Eksp Biol Med 1981 May; 91 (5): 537-9
21. Mamelak M. Gammahydroxybutyrate: an endogenous regulator of energy metabolism. Neurosci Biobehav Rev 1989 Winter; 13 (4): 187-98
22. Ueki Y. Effects of gamma-hydroxybutyrate on monoamine metabolism and protein synthesis after transient global cerebral ischemia [in Japanese]. No Shinkei Geka 1992 Sep; 20 (9): 937-46
23. Geldenhuys FG, Sonnendecker EW, De Klerk MC. Experience with sodium-gamma-4-hydroxybutyric acid (gamma-OH) in obstetrics. J Obstet Gynaecol Br Commonw 1968 Apr; 75 (4): 405-13
24. Ferrara SD, Giorgetti R, Zancaner S, et al. Effects of single dose of gamma-hydroxybutyric acid and lorazepam on psychomotor performance and subjective feelings in healthy volunteers. Eur J Clin Pharmacol 1999 Jan; 54 (11): 821-7
25. Addolorato G, Castelli E, Stefanini GF, et al. An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects: GHB Study Group. Alcohol Alcohol 1996 Jul; 31 (4): 341-5
26. Ferrara SD, Zotti S, Tedeschi L, et al. Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses. Br J Clin Pharmacol 1992 Sep; 34 (3): 231-5
27. Gallimberti L, Ferri M, Ferrara SD, et al. Gamma-hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study. Alcohol Clin Exp Res 1992 Aug; 16 (4): 673-6
28. Biggio G, Cibin M, Diana M, et al. Suppression of voluntary alcohol intake in rats and alcoholics by gamma-hydroxybutyric acid: a non-GABAergic mechanism. Adv Biochem Psychopharmacol 1992; 47: 281-8
29. Gallimberti L, Canton G, Gentile N, et al. Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. Lancet 1989 Sep 30; 2 (8666): 787-9
30. Maremmani I, Lamanna F, Tagliamonte A. Long-term therapy using GHB (sodium gamma hydroxybutyrate) for treatment-resistant chronic alcoholics. J Psychoactive Drugs 2001 Apr-Jun; 33 (2): 135-42
31. Nimmerrichter AA, Walter H, Gutierrez-Lobos KE, et al. Double-blind controlled trial of gamma-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal. Alcohol 2002 Jan-Feb; 37 (1): 67-73
32. Bowles TM, Sommi RW, Amiri M. Successful management of prolonged gamma-hydroxybutyrate and alcohol withdrawal. Pharmacotherapy 2001 Feb; 21 (2): 254-7
33. Gallimberti L, Spella MR, Soncini CA, et al. Gamma-hydroxybutyric acid in the treatment of alcohol and heroin dependence. Alcohol 2000 Apr; 20 (3): 257-62
34. Gallimberti L, Cibin M, Pagnin P, et al. Gamma-hydroxybutyric acid for treatment of opiate withdrawal syndrome. Neuropsychopharmacology 1993 Aug; 9 (1): 77-81
35. Scharf MB, Baumann M, Berkowitz DV. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol 2003 May; 30 (5): 1070-4
36. Scharf MB, Hauck M, Stover R, et al. Effect of gamma-hydroxybutyrate on pain, fatigue, and the alpha sleep anomaly in patients with fibromyalgia: preliminary report. J Rheumatol 1998 Oct; 25 (10): 1986-90
37. Rinaldi F, Puca FM, Mastrosimone F, et al. On the use of gamma-hydroxybutyrate of sodium in psychiatric therapy [in Italian]. Acta Neurol (Napoli) 1967 Jan-Feb; 22 (1): 21-41
38. Martellotta MC, Balducci C, Fattore L, et al. Gamma-hydroxybutyric acid decreases intravenous cocaine self-administration in rats. Pharmacol Biochem Behav 1998 Mar; 59 (3): 697-702
39. Vescovi PP, Di Gennaro C. Failure of gammahydroxy butyric acid to stimulate growth hormone secretion in cocaine addicts. Neuropeptides 1997; 31 (5): 459-62
40. Frucht SJ, Bordelon Y, Houghton WH. Marked amelioration of alcohol-responsive posthypoxic myoclonus by gamma-hydroxybutyric acid (Xyrem). Mov Disord 2005; 20 (6): 745-51
41. Frucht SJ, Bordelon Y, Houghton WH, et al. A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsibe movement disorders. Mov Disord 2005; 20 (10): 1330-7
42. Frucht SJ, Houghton WC, Bordelon Y, et al. A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor. Neurology 2005; 65 (12): 1967-9
43. Rubin BA, Giarman NJ. The therapy of experimental influenza in mice with antibiotic lactones and related compounds. Yale J Biol Med 1947; 19: 1017-22
44. Lapierre O, Montplaisir J, Lamarre M, et al. The effect of gamma-hydroxybutyrate on nocturnal and diurnal sleep of normal subjects: further considerations on REM sleep-triggering mechanisms. Sleep 1990 Feb; 13 (1): 24-30
45. Mamelak M, Escriu JM, Stokan O. Sleep-inducing effects of gammahydroxybutyrate. Lancet 1973 Aug 11; 2 (7824): 328-9
46. Fuller DE, Hornfeldt CS, Kelloway JS, et al. The Xyrem. risk management program. Drug Saf 2004; 27 (5): 293-306
47. Xyrem® International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med 2005 Sep; 6 (5): 415-21
48. US Drug Enforcement Administration. Gamma hydroxybutyric acid (GHB, liquid X, Goop, Georgia Home Boy) [online]. Available from URL: http://www.usdoj.gov/dea/pubs/pressrel/pr031300_01.htm [Accessed 2000 Mar 13]
49. Galloway GP, Frederick SL, Staggers Jr FE, et al. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction 1997 Jan; 92 (1): 89-96
50. Craig K, Gomez HF, McManus JL, et al. Severe gamma-hydroxybutyrate withdrawal: a case report and literature review. J Emerg Med 2000 Jan; 18 (1): 65-70
51. Woolverton WL, Rowlett JK, Winger G, et al. Evaluation of the reinforcing and discriminative stimulus effects of gamma-hydroxybutyrate in rhesus monkeys. Drug Alcohol Depend 1999 Apr 1; 54 (2): 137-43
52. McMahon LR, Coop A, France CP, et al. Evaluation of the reinforcing and discriminative stimulus effects of 1,4-butanediol and gamma-butyrolactone in rhesus monkeys. Eur J Pharmacol 2003 Apr 11; 466 (1-2): 113-20
53. Carter LP, Richards BD, Mintzer MZ, et al. Relative abuse liability of GHB in humans: a comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Neuropsychopharmacolochogy 2006; 31 (11): 2537-51.
54. Anderson IB, Kim SY, Dyer JE, et al. Trends in gamma-hydroxybutyrate (GHB) and related drug intoxication: 1999 to 2003. Ann Emerg Med 2006 Feb; 47 (2): 177-83
55. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug abuse warning network, 2003: interim national estimates of drug-related emergency department visits. DAWN series D-26. Rockville (MD): DHHS publication no. (SMA) 04-3972, 2004
56. Slaughter L. Involvement of drugs in sexual assault. J Reprod Med 2000 May; 45 (5): 425-30
57. Doherty JD, Snead OC, Roth RH. A sensitive method for quantitation of gamma-hydroxybutyric acid and gamma-butyrolactone in brain by electron capture gas chromatography. Anal Biochem 1975 Nov; 69 (1): 268-77
58. Ehrhardt JD, Vayer P, Maitre M. A rapid and sensitive method for the determination of gamma-hydroxybutyric acid and trans-gamma-hydroxycrotonic acid in rat brain tissue by gas chromatography/mass spectrometry with negative ion detection. Biomed Environ Mass Spectrom 1988 May 15; 15 (10): 521-4
59. Snead III OC. Gamma-hydroxybutyric acid in subcellular fractions of rat brain. J Neurochem 1987 Jan; 48 (1): 196-201
60. Snead III OC, Morley BJ. Ontogeny of gamma-hydroxybutyric acid: I. Regional concentration in developing rat, monkey and human brain. Brain Res 1981 Jul; 227 (4): 579-89
61. Nelson T, Kaufman E, Kline J, et al. The extraneural distribution of gamma-hydroxybutyrate. J Neurochem 1981 Nov; 37 (5): 1345-8
62. Gold BI, Roth RH. Kinetics of in vivo conversion of gamma-[3H] aminobutyric acid to gamma-[3H]hydroxybutyric acid by rat brain. J Neurochem 1977; 28: 1069-73
63. Weissmann-Nanopoulos D, Belin MF, Mandel P, et al. Immunocytochemical evidence for the presence of enzymes synthesizing GABA and GHB in the same neuron. Neurochem Intl 1984; 6: 333-8
64. Rumigny JF, Cash C, Mandel P, et al. Evidence that a specific succinic semialdehyde reductase is responsible for gamma-hydroxybutyrate synthesis in brain tissue slices. FEBS Lett 1981 Nov 2; 134 (1): 96-8
65. Maitre M. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol 1997 Feb; 51 (3): 337-61
66. Eli M, Cattabeni F. Endogenous gamma-hydroxybutyrate in rat brain areas: postmortem changes and effects of drugs interfering with gamma-aminobutyric acid metabolism. J Neurochem 1983 Aug; 41 (2): 524-30
67. Rumigny JF, Cash C, Mandel P, et al. Ontogeny and distribution of specific succinic semialdehyde reductase apoenzyme in the rat brain. Neurochem Res 1982 May; 7 (5): 555-61
68. Rumigny JF, Maitre M, Cash C, et al. Regional and subcellular localization in rat brain of the enzymes that can synthesize gamma-hydroxybutyric acid. J Neurochem 1981 Apr; 36 (4): 1433-8
69. Hearl WG, Churchich JE. A mitochondrial NADP+-dependent reductase related to the 4-aminobutyrate shunt. J Biol Chem 1985; 260: 16361-6
70. Cho SW, Song MS, Kim GY, et al. Kinetics and mechanism of an NADPH-dependent succinic semialdehyde reductase from bovine brain. Eur J Biochem 1993; 211: 757-62
71. Barker SA, Snead OC, Poldrugo F, et al. Identification and quantitation of 1,4-butanediol in mammalian tissues: an alternative biosynthetic pathway for gamma-hydroxybutyric acid. Biochem Pharmacol 1985 May 15; 34 (10): 1849-52
72. Roth RH, Levy R, Giarman NJ. Dependence of rat serum lactonase upon calcium. Biochem Pharmacol 1967; 16: 596-8
73. Doherty JD, Stout RW, Roth RH. Metabolism of [1-14C] gamma-hydroxybutyric acid by rat brain after intraventricular injection. Biochem Pharmacol 1975; 24: 469-74
74. Mohler H, Patel AJ, Balazs R. Gamma-hydroxybutyrate degradation in the brain in vivo: negligible direct conversion to GABA. J Neurochem 1976 Jul; 27 (1): 253-8
75. Vayer P, Schmitt M, Bourguignon JJ, et al. Evidence for a role of high Km aldehyde reductase in the degradation of endogenous gamma-hydroxybutyrate from rat brain. FEBS Lett 1985 Oct 7; 190 (1): 55-60
76. Kaufman EE, Nelson T, Goochee C, et al. Purification and characterization of an NADP+-linked alcohol oxido-reductase which catalyzes the interconversion of gamma-hydroxybutyrate and succinic semialdehyde. J Neurochem 1979; 32: 699-712
77. Kaufman EE, Nelson T. Evidence for the participation of a cytosolic NADP+-dependent oxidoreductase in the catabolism of gamma-hydroxybutyrate in vivo. J Neurochem 1987 Jun; 48 (6): 1935-41
78. Kaufman EE, Relkin N, Nelson T. Regulation and properties of an NADP+ oxidoreductase which functions as a gamma-hydroxybutyrate dehydrogenase. J Neurochem 1983 Jun; 40 (6): 1639-46
79. Kaufman EE, Nelson T. Kinetics of coupled gamma-hydroxybutyrate oxidation and D-glucuronate reduction by an NADP+-dependent oxidoreductase. J Biol Chem 1981; 256: 6890-4
80. Kaufman EE, Nelson T. An overview of gamma-hydroxybutyrate catabolism: the role of the cytosolic NADP(+)-dependent oxidoreductase EC 1.1.1.19 and of a mitochondrial hydroxyacid-oxoacid transhydrogenase in the initial, rate-limiting step in this pathway. Neurochem Res 1991 Sep; 16 (9): 965-74
81. Taberner PN, Rick JT, Kerkut GA. The action of gamma-hydroxybutyric acid on cerebral glucose metabolism. J Neurochem 1972; 12: 245-54
82. Snead OC, Bearden LJ, Pegram V. Effect of acute and chronic anticonvulsant administration on endogenous gamma-hydroxybutyrate in rat brain. Neuropharmacology 1980; 12: 47-52
83. Gibson K. Gamma-hydroxybutyric aciduria: a biochemist's education from a heritable disorder of GABA metabolism. J Inherit Metab Dis 2005; 28 (3): 247-65
84. Kaufman EE, Nelson T, Miller D, et al. Oxidation of gamma-hydroxybutyrate to succinic semialdehyde by a mitochondrial pyridine nucleotide-independent enzyme. J Neurochem 1988 Oct; 51 (4): 1079-84
85. Crunelli V, Emri Z, Leresche N. Unravelling the brain targets of gamma-hydroxybutyric acid. Curr Opin Pharmacol 2006 Feb; 6 (1): 44-52
86. Mitoma C, Neubauer SE. Gamma-hydroxybutyric acid and sleep. Experientia 1968 Jan 15; 24 (1): 12-3
87. Margolis RK. The effect of gamma-hydroxybutyric acid on amino acid levels in brain. Biochem Pharmacol 1969 May; 18 (5): 1243-6
88. Vayer P, Mandel P, Maitre M. Conversion of gamma-hydroxybutyrate to gamma-aminobutyrate in vitro. J Neurochem 1985 Sep; 45 (3): 810-4
89. Vayer P, Dessort D, Bourguignon JJ, et al. Natural occurrence of trans-gamma hydroxycrotonic acid in rat brain. Biochem Pharmacol 1985 Jul 1; 34 (13): 2401-4
90. Walkenstein SS, Wiser R, Gudmundsen C, et al. Metabolism of gamma-hydroxybutyric acid. Biochim Biophys Acta 1964 Jun 8; 86: 640-2
91. Maitre M, Mandel P. Calcium-dependent liberation of gamma-hydroxybutyrate after depolarization of rat brain slices [in French]. C R Seances Acad Sci III 1982 Dec 6; 295 (12): 741-3
92. Maitre M, Cash C, Weissmann-Nanopoulos D, et al. Depolarization-evoked release of gamma-hydroxybutyrate from rat brain slices. J Neurochem 1983 Jul; 41 (1): 287-90
93. Vayer P, Maitre M. Regional differences in depolarization-induced release of gamma-hydroxybutyrate from rat brain slices. Neurosci Lett 1988 Apr 22; 87 (1-2): 99-103
94. Benavides J, Rumigny JF, Bourguignon JJ, et al. High affinity binding sites for gamma-hydroxybutyric acid in rat brain. Life Sci 1982 Mar 15; 30 (11): 953-61
95. Hechler V, Bourguignon JJ, Wermuth CG, et al. Gamma-hydroxybutyrate uptake by rat brain striatal slices. Neurochem Res 1985 Mar; 10 (3): 387-96
96. Maitre M, Rumigny JF, Benavides J, et al. High affinity binding site for gamma-hydroxybutyric acid in rat brain. Adv Biochem Psychopharmacol 1983; 37: 441-53
97. Snead III OC, Liu CC. Gamma-hydroxybutyric acid binding sites in rat and human brain synaptosomal membranes. Biochem Pharmacol 1984 Aug 15; 33 (16): 2587-90
98. Ratomponirina C, Hode Y, Hechler V, et al. Gamma-hydroxybutyrate receptor binding in rat brain is inhibited by guanyl nucleotides and pertussis toxin. Neurosci Lett 1995 Apr 7; 189 (1): 51-3
99. Mamelak M. Hyndman D. Gamma-hydroxybutyrate and oxidative stress. In: Tunnicliffe G, Cash C, editors. Gamma-hydroxybutyrate: molecular, clinical and functional aspects. New York: Taylor & Francis, 2002: 218-35
100. Hechler V, Weissmann D, Mach E, et al. Regional distribution of high-affinity gamma-[3H]hydroxybutyrate binding sites as determined by quantitative autoradiography. J Neurochem 1987 Oct; 49 (4): 1025-32
101. Hechler V, Gobaille S, Maitre M. Selective distribution pattern of gamma-hydroxybutyrate receptors in the rat forebrain and midbrain as revealed by quantitative autoradiography. Brain Res 1992 Feb 14; 572 (1-2): 345-8
102. Kaupmann K, Cryan JF, Wellendorph P, et al. Specific gamma- hydroxybutyrate-binding sites but loss of pharmacological effects of gamma-hydroxybutyrate in GABA(B)(1)-deficient mice. Eur J Neurosci 2003 Nov; 18 (10): 2722-30
103. Kawaguchi Y, Wilson CJ, Augood SJ, et al. Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci 1995 Dec; 18 (12): 527-35
104. Maitre M, Ratomponirina C, Gobaille S, et al. Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics. Eur J Pharmacol 1994 Apr 21; 256 (2): 211-4
105. Kemmel V, Taleb O, Perard A, et al. Neurochemical and electrophysiological evidence for the existence of a functional gamma-hydroxybutyrate system in NCB-20 neurons. Neuroscience 1998 Oct; 86 (3): 989-1000
106. Cash CD, Gobaille S, Kemmel V, et al. Gamma-hydroxybutyrate receptor function studied by the modulation of nitric oxide synthase activity in rat frontal cortex punches. Biochem Pharmacol 1999 Dec 1; 58 (11): 1815-9
107. Olpe HR, Koella WP. Inhibition of nigral and neocortical cells by gamma-hydroxybutyrate: a microiontophoretic investigation. Eur J Pharmacol 1979 Feb 1; 53 (4): 359-64
108. Kozhechkin SX. Microiontophoretic study of the mechanism of action of gamma-hydroxybutyric acid. Bull Expl Biol Med 1979; 88 (5): 1293-6
109. Mathivet P, Bernasconi R, De Barry J, et al. Binding characteristics of gamma-hydroxybutyric acid as a weak but selective GABA(B) receptor agonist. Eur J Pharmacol 1997 Feb 19; 321 (1): 67-75
110. Bernasconi R, Lauber J, Marescaux C, et al. Experimental absence seizures: potential role of gamma-hydroxybutyric acid and GABA(B) receptors. J Neural Transm Suppl 1992; 35: 155-77
111. Madden TE, Johnson SW. Gamma-hydroxybutyrate is a GABA(B) receptor agonist that increases a potassium conductance in rat ventral tegmental dopamine neurons. J Pharmacol Exp Ther 1998 Oct; 287 (1): 261-5
112. Ocana M, Cendan CM, Cobos EJ, et al. Potassium channels and pain: present realities and future opportunities. Eur J Pharmacol 2004 Oct 1; 500 (1-3): 203-19
113. Lingenhoehl K, Brom R, Heid J, et al. Gamma-hydroxybutyrate is a weak agonist at recombinant GABA(B) receptors. Neuropharmacology 1999 Nov; 38 (11): 1667-73
114. Xie X, Smart TG. Gamma-hydroxybutyrate hyperpolarizes hippocampal neurones by activating GABA(B) receptors. Eur J Pharmacol 1992 Mar 3; 212 (2-3): 291-4
115. Engberg G, Nissbrandt H. Gamma-hydroxybutyric acid (GHBA) induces pacemaker activity and inhibition of substantia nigra dopamine neurons by activating GABA(B)-receptors. Naunyn Schmiedebergs Arch Pharmacol 1993 Nov; 348 (5): 491-7
116. Williams SR, Turner JP, Crunelli V. Gamma-hydroxybutyrate promotes oscillatory activity of rat and cat thalamocortical neurons by a tonic GABA(B), receptor-mediated hyperpolarization. Neuroscience 1995 May; 66 (1): 133-41
117. Godbout R, Pivik RT. EEG and behavioral effects of gamma-hydroxybutyrate in the rabbit. Life Sci 1982 Aug 23; 31 (8): 739-48
118. Snead III OC. Evidence for a G protein-coupled gamma-hydroxybutyric acid receptor. J Neurochem 2000 Nov; 75 (5): 1986-96
119. Vayer P, Gobaille S, Mandel P, et al. 3′-5′ Cyclic-guanosine monophosphate increase in rat brain hippocampus after gamma-hydroxybutyrate administration: prevention by valproate and naloxone. Life Sci 1987 Aug 3; 41 (5): 605-10
120. Ito Y, Ishige K, Zaitsu E, et al. Gamma-hydroxybutyric acid increases intracellular Ca2+ concentration and nuclear cyclic AMP-responsive element- and activator protein 1 DNA-binding activities through GABA(B) receptor in cultured cerebellar granule cells. J Neurochem 1995 Jul; 65 (1): 75-83
121. Vayer P, Maitre M. Gamma-hydroxybutyrate stimulation of the formation of cyclic GMP and inositol phosphates in rat hippocampal slices. J Neurochem 1989 May; 52 (5): 1382-7
122. Shumate JS, Snead III OC. Plasma and central nervous system kinetics of gamma-hydroxybutyrate. Res Commun Chem Pathol Pharmacol 1979 Aug; 25 (2): 241-56
123. Lettieri JT, Fung HL. Dose-dependent pharmacokinetics and hypnotic effects of sodium gamma-hydroxybutyrate in the rat. J Pharmacol Exp Ther 1979 Jan; 208 (1): 7-11
124. Roth RH, Doherty JD, Walters JR. Gamma-hydroxybutyrate: a role in the regulation of central dopaminergic neurons? Brain Res 1980 May 12; 189 (2): 556-60
125. Nissbrandt H, Elverfors A, Engberg G. Pharmacologically induced cessation of burst activity in nigral dopamine neurons: significance for the terminal dopamine efflux. Synapse 1994 Aug; 17 (4): 217-24
126. Bustos G, Kuhar MJ, Roth RH. Effect of gamma-hydroxybutyrate and gamma-butyrolactone on dopamine synthesis and uptake by rat striatum. Biochem Pharmacol 1972 Oct 1; 21 (19): 2649-52
127. Bustos G, Roth RH. Release of monoamines from the striatum and hypothalamus: effect of gamma-hydroxybutyrate. Br J Pharmacol 1972 Sep; 46 (1): 101-15
128. Da Prada M, Keller HH. Baclofen and gamma-hydroxybutyrate: similar effects on cerebral dopamine neurones. Life Sci 1976 Oct 15; 19 (8): 1253-63
129. Kelly PH, Moore KE. Dopamine concentrations in the rat brain following injections into the substantia nigra of baclofen, gamma-aminobutyric acid, gamma-hydroxybutyric acid, apomorphine and amphetamine. Neuropharmacology 1978 Mar; 17 (3): 169-74
130. Broxterman HJ, Noach EL, van Valkenburg CF, et al. Cross-tolerance of dopamine metabolism to baclofen, gamma-butyrolactone and HA-966 in the striatum and olfactory tubercle of the rat. Life Sci 1981 Mar 2; 28 (9): 973-81
131. Waldmeier PC, Fehr B. Effects of baclofen and gamma-hydroxybutyrate on rat striatal and mesolimbic 5-HT metabolism. Eur J Pharmacol 1978 May 15; 49 (2): 177-84
132. Gessa GL, Vargiu L, Crabai F, et al. Selective increase of brain dopamine induced by gamma hydroxybutyrate. J Neurochem 1968; 15 (5): 377-81
133. Gessa GL, Crabai F, Vargiu L, et al. Selective increase of brain dopamine induced by gamma-hydroxybutyrate: study of the mechanism of action. J Neurochem 1968; 15: 377-81
134. Aghajanian GK, Roth RH. Gamma-hydroxybutyrate-induced increase in brain dopamine: localization by fluorescence microscopy. J Pharmacol Exp Ther 1970 Oct; 175 (1): 131-8
135. Spano PF, Tagliamonte A, Tagliamonte P, et al. Stimulation of brain dopamine synthesis by gamma-hydroxybutyrate. Neurochem 1971 Oct; 18 (10): 1831-6
136. Pericic D, Walters JR. Dopamine in substantia nigra and cortex after gamma-butyrolactone treatment. J Pharm Pharmacol 1976 Jun; 28 (6): 527-30
137. Lundborg P, Hedner T, Engel J. Catecholamine concentration in the developing rat brain after gamma-hydroxybutyric acid. Neurochem 1980 Aug; 35 (2): 425-9
138. Dyck LE, Kazakoff CW. Acceleration of the biosynthesis of rat striatal dopamine by incubation and by administration of gamma-butyrolactone. J Neurosci Res 1982; 8 (1): 57-65
139. Roth RH, Suhr Y. Mechanism of the gamma-hydroxybutyrate-induced increase in brain dopamine and its relationship to "sleep". Biochem Pharmacol 1970 Dec; 19 (12): 3001-12
140. Walters JR, Roth RH. Dopaminergic neurons: drug-induced antagonism of the increase in tyrosine hydroxylase activity produced by cessation of impulse flow. J Pharmacol Exp Ther 1974 Oct; 191 (1): 82-91
141. Walters JR, Roth RH. Dopaminergic neurons: alteration in the sensitivity of tyrosine hydroxylase to inhibition by endogenous dopamine after cessation of impulse flow. Biochem Pharmacol 1976 Mar 15; 25 (6): 649-54
142. Zivkovic B, Guidotti A, Costa E. The regulation of striatal tyrosine hydroxylase. Effects of gamma hydroxybutric acid and healperidol. Naunyn Schmiedebergs Arch Pharmacol 1975 Nov 21; 291 (2): 193-200
143. Roth RH, Nowycky MC, Walters JR, et al. Gamma-hydroxybutyrate: effects on nonstriatal dopaminergic neurons. Adv Biochem Psychopharmacol 1977; 16: 483-8
144. Hedner T, Lundborg P. Effect of gammahydroxybutyric acid on catecholamine synthesis and utilization in the developing rat brain. J Neural Transm 1982; 54 (1-2): 19-28
145. Arluison M, Javoy-Agid F, Feuerstein C, et al. Histofluorescence analysis of several systems of catecholaminergic nerve fibres within the rat neostriatum revealed by either restricted lesions of the substantia nigra or gamma-hydroxybutyrate. Brain Res Bull 1982 Jul-Dec; 9 (1-6): 355-65
146. Tunnicliff G. Significance of gamma-hydroxybutyric acid in the brain. Gen Pharmacol 1992 Nov; 23 (6): 1027-34
147. Cheramy A, Nieoullon A, Glowinski J. Stimulating effects of gamma-hydroxybutyrate on dopamine release from the caudate nucleus and the substantia nigra of the cat. J Pharmacol Exp Ther 1977 Nov; 203 (2): 283-93
148. Hechler V, Gobaille S, Bourguignon JJ, et al. Extracellular events induced by gamma-hydroxybutyrate in striatum: a microdialysis study. J Neurochem 1991 Mar; 56 (3): 938-44
149. Biggio G, Casu M, Corda MG, et al. Effect of muscimol, a GABA-mimetic agent, on dopamine metabolism in the mouse brain. Life Sci 1977 Aug 15; 21 (4): 525-31
150. Snead III OC, Bearden LJ. Naloxone overcomes the dopaminergic, EEG, and behavioral effects of gamma-hydroxybutyrate. Neurology 1980 Aug; 30 (8): 832-8
151. Dingledine R, Iversen LL, Breuker E. Naloxone as a GABA antagonist: evidence from iontophoretic, receptor binding and convulsant studies. Eur J Pharmacol 1978 Jan 1; 47 (1): 19-27
152. Schmidt-Mutter C, Muller C, Zwiller J, et al. Gamma-hydroxybutyrate and cocaine administration increases mRNA expression of dopamine D1 and D2 receptors in rat brain. Neuropsychopharmacology 1999 Nov; 21 (5): 662-9
153. Spano PF, Przegalinski E. Stimulation of serotonin synthesis by anesthetic and non-anesthetic doses of gamma-hydroxybutyrate. Pharmacol Res Commun 1973; 5: 55-69
154. Miguez I, Aldegunde M, Duran R, et al. Effect of low doses of gamma-hydroxybutyric acid on serotonin, noradrenaline, and dopamine concentrations in rat brain areas. Neurochem Res 1988 Jun; 13 (6): 531-3
155. Bustos G, Roth RH. Effect of gamma-hydroxybutyrate on the release of monoamines from the rat striatum. Br J Pharmacol 1972 Apr; 44 (4): 817-20
156. Boadle-Biber MC. Biosynthesis of serotonin. In: Osborne NN, editor. Biology of serotonergic transmission. Chichester: Wiley, 1982: 63-94
157. Gerra G, Caccavari R, Fontanesi B, et al. Naloxone and metergoline effects on growth hormone response to gamma-hydroxybutyric acid. Int Clin Psychopharmacol 1995 Nov; 10 (4): 245-50
158. Delitala G, Masala A, Alagna S, et al. Growth hormone and prolactin release in acromegalic patients following metergoline administration. J Clin Endocrinol Metab 1976 Dec; 43 (6): 1382-6
159. Lason W, Przewlocka B, Przewlocki R. The effect of gamma-hydroxybutyrate and anticonvulsants on opioid peptide content in the rat brain. Life Sci 1983; 33 Suppl. 1: 599-602
160. Schmidt-Mutter C, Gobaille S, Muller C, et al. Prodynorphin and proenkephalin mRNAs are increased in rat brain after acute and chronic administration of gamma-hydroxybutyrate. Neurosci Lett 1999 Feb 26; 262 (1): 65-8
161. Vayer P, Mandel P, Maitre M. Gamma-hydroxybutyrate, a possible neurotransmitter. Life Sci 1987 Sep 28; 41 (13): 1547-57
162. Crosby G, Ito M, Kaufman E, et al. Naloxone pretreatment alters the local cerebral metabolic effect of gamma-hydroxybutyrate in rats. Brain Res 1983 Sep 19; 275 (1): 194-7
163. Devoto P, Colombo G, Cappai F, et al. Naloxone antagonizes ethanol- but not gamma-hydroxybutyrate-induced sleep in mice. Eur J Pharmacol 1994 Feb 11; 252 (3): 321-4
164. Gobaille S, Schmidt C, Cupo A, et al. Characterization of methionine-enkephalin release in the rat striatum by in vivo dialysis: effects of gamma-hydroxybutyrate on cellular and extracellular methionine-enkephalin levels. Neuroscience 1994 Jun; 60 (3): 637-48
165. Dingledine R, Iversen LL, Breuker E. Naloxone as a GABA antagonist: evidence from iontophoretic receptor binding and convulsant studies. Eur J Pharmacol 1978; 47: 19-27
166. Sethy VH, Roth RH, Walters JR, et al. Effect of anesthetic doses of gamma-hydroxybutyrate on the acetylcholine content of rat brain. Naunyn Schmiedebergs Arch Pharmacol 1976 Oct 12; 295 (1): 9-14
167. Nava F, Carta G, Bortolato M, et al. Gamma-hydroxybutyric acid and baclofen decrease extracellular acetylcholine levels in the hippocampus via GABA(B) receptors. Eur J Pharmacol 2001 Nov 2; 430 (2-3): 261-3
168. Shefner SA, Osmanovic SS. GABA(A) and GABA(B) receptors and the ionic mechanisms mediating their effects on locus coeruleus neurons. Prog Brain Res 1991; 88: 187-95
169. Persson B, Henning M. Central cardiovascular effects of gamma-hydroxybutyric acid: interactions with noradrenaline, serotonin, dopamine and acetylcholine transmission. Acta Pharmacol Toxicol (Copenh) 1980 Nov; 47 (5): 335-46
170. Szabo ST, Gold MS, Goldberger BA, et al. Effects of sustained gamma-hydroxybutyrate treatments on spontaneous and evoked firing activity of locus coeruleus norepinephrine neurons. Biol Psychiatry 2004 May 1; 55 (9): 934-9
171. Espana R A, Scammell TE. Sleep neurobiology for the clinician. Sleep 2004; 27 (4): 811-20
172. Broughton R, Mamelak M. Effects of nocturnal gamma-hydroxybutyrate on sleep/waking patterns in narcolepsy-cataplexy. Can J Neurol Sci 1980 Feb; 7 (1): 23-31
173. Mamelak M, Black J, Montplaisir J, et al. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 2004 Nov 1; 27 (7): 1327-34
174. Mamelak M, Escriu JM, Stokan O. The effects of gamma-hydroxybutyrate on sleep. Biol Psychiatry 1977; 12: 273-88
175. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002 Feb 1; 25 (1): 42-9
176. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004; 5 (2): 119-23
177. The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms. J Toxicol Clin Toxicol 2003; 41 (2): 131-5
178. Galloway GP, Frederick-Osborne SL, Seymour R, et al. Abuse and therapeutic potential of gamma-hydroxybutyric acid. Alcohol 2000; 20 (3): 263-9
179. Ferraro L, Tanganelli S, O'Connor WT, et al. Gamma-hydroxybutyrate modulation of glutamate levels in the hippocampus: an in vivo and in vitro study. J Neurochem 2001 Sep; 78 (5): 929-39
180. Berton F, Brancucci A, Beghe F, et al. Gamma-hydroxybutyrate inhibits excitatory postsynaptic potentials in rat hippocampal slices. Eur J Pharmacol 1999 Sep 10; 380 (2-3): 109-16
181. King M, Thinschmidt JS, Walker DW. Gammahydroxybutyrate (GHB) receptor ligand effects on evoked synaptic field potentials in CA1 of the rat hippocampal slice. J Neural Transm 1997; 104 (11-12): 1177-93
182. Banerjee PK, Snead III OC. Presynaptic gamma-hydroxybutyric acid (GHB) and gamma-aminobutyric acidB (GABA(B)) receptor-mediated release of GABA and glutamate (GLU) in rat thalamic ventrobasal nucleus (VB): a possible mechanism for the generation of absence-like seizures induced by GHB. J Pharmacol Exp Ther 1995 Jun; 273 (3): 1534-43
183. Oyama T, Takiguchi M. Effects of gamma-hydroxybutyrate and surgery on plasma human growth hormone and insulin levels. Agressologie 1970; 11 (3): 289-98
184. Van Cauter E, Plat L, Scharf MB, et al. Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young men. J Clin Invest 1997 Aug 1; 100 (3): 745-53
185. Van Cauter E, Gopinschi C. Interrelationships between growth hormone and sleep. Growth Horm IGF Res 2000 Apr; 10 Suppl. B: S57-62
186. Gerra G, Caccavari R, Fontanesi B, et al. Flumazenil effects on growth hormone response to gamma-hydroxybutyric acid. Int Clin Psychopharmacol 1994 Sep; 9 (3): 211-5
187. Volpi R, Chiodera P, Caffarra P, et al. Different control mechanisms of growth hormone (GH) secretion between gamma-amino-and gamma-hydroxy-butyric acid: neuroendocrine evidence in Parkinson's disease. Psychoneuroendocrinology 1997 Oct; 22 (7): 531-8
188. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998 Dec; 19 (6): 717-97
189. Volpi R, Chiodera P, Caffarra P, et al. Muscarinic cholinergic mediation of the GH response to gamma-hydroxybutyric acid: neuroendocrine evidence in normal and parkinsonian subjects. Psychoneuroendocrinology 2000 Feb; 25 (2): 179-85
190. Barbaccia ML, Carai MA, Colombo G, et al. Endogenous gamma-aminobutyric acid (GABA)(A) receptor active neurosteroids and the sedative/hypnotic action of gamma-hydroxybutyric acid (GHB): a study in GHB-S (sensitive) and GHB-R (resistant) rat lines. Neuropharmacology 2005 Jul; 49 (1): 48-58
191. Laborit H. Correlations between protein and serotonin synthesis during various activities of the central nervous system (slow and desynchronized sleep, learning and memory, sexual activity, morphine tolerance, aggressiveness, and pharmacological action of sodium gamma-hydroxybutyrate). Res Commun Chem Pathol Pharmacol 1972 Jan; 3 (1): 51-81
192. Jouvet M, Cier A, Mounier D, et al. Effect of sodium 4-hydroxybutyrate and 4-butyrolactone on cat EEG and behavior [in French]. C R Seances Soc Biol Fil 1961; 155: 1313-6
193. Winters WD, Spooner CE. Various seizure activities following gamma-hydroxybutyrate. Int J Neuropharmacol 1965; 31: 197-200
194. Godschalk M, Dzoljic MR, Bonta IL, et al. Slow wave sleep and a state resembling absence epilepsy induced in the rat by gamma-hydroxybutyrate. Eur J Pharmacol 1977; 44 (2): 105-11
195. Marcus RJ, Winters WD, Mori K, et al. EEG and behavioral comparison of the effects of gamma-hydroxybutyrate, gamma-butyrolactone and short chain fatty acids in the rat. Int J Neuropharmacol 1967 May; 6 (3): 175-85
196. Laborit H, Buchard F, Laborit G, et al. Use of sodium 4-hydroxybutyrate in anesthesia and resuscitation [in French]. Agressologie 1960: 1: 549-60.
197. Laborit H, Jouany JM, Gerard J, et al. Generalities concerning the experimental study and clinical use of gamma hydroxybutyrate of Na [in French]. Agressologie 1960: 1: 397-406.
198. Laborit H, Jouany JM, Gerard J, et al. Summary of an experimental and clinical study on a metabolic substrate with inhibitory central action: sodium 4-hydroxybutyrate [in French]. Presse Med 1960; 68: 1867-9.
199. Jouany JM, Gerard J, Weber B, et al. Interference of various pharmacological agents with the establishment and character of sleep induced by 4-hydroxybutyric acid [in French]. Agressologie 1961; 2: 45-7
200. Reder A, Mednick AS, Brown P, et al. Clinical and genetic studies of fatal familial insomnia. Neurology 1995 Jun; 45 (6): 1068-75
201. Moldofsky H, Scarisbrick P, England R, et al. Musculosketal symptoms and non-REM sleep disturbance in patients with 'fibrositis syndrome' and healthy subjects. Psychosom Med 1975 Jul-Aug; 37 (4): 341-51
202. Moldofsky H. Sleep and musculoskeletal pain. Am J Med 1986 Sep 29; 81 (3A): 85-9
203. Lentz MJ, Landis CA, Rothermel J, et al. Effects of selective slow wave sleep disruption on musculoskeletal pain and fatigue in middle aged women. J Rheumatol 1999 Jul; 26 (7): 1586-92
204. Broughton R, Mamelak M. Gamma-hydroxybutyrate in the treatment of compound narcolepsy: a preliminary report: I. New York: Spectrum, 1976
205. Broughton R, Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate. Can J Neurol Sci 1979 Feb; 6 (1): 1-6
206. Mamelak M, Scharf MB, Woods M. Treatment of narcolepsy with gamma-hydroxybutyrate: a review of clinical and sleep laboratory findings. Sleep 1986; 9 (1 Pt 2): 285-9
207. Scharf MB, Brown D, Woods M, et al. The effects and effectiveness of gamma-hydroxybutyrate in patients with narcolepsy. J Clin Psychiatry 1985 Jun; 46 (6): 222-5
208. Scrima L, Hartman PG, Johnson Jr FH, et al. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures. Biol Psychiatry 1989 Aug; 26 (4): 331-43
209. Moldofsky H, Scarisbrick P, England R, et al. Musculosketal symptoms and non-REM sleep disturbance in patients with 'fibrositis syndrome' and healthy subjects. Psychosom Med 1975 Jul-Aug; 37 (4): 341-51
210. Moldofsky H. Sleep and musculoskeletal pain. Am J Med 1986 Sep 29; 81 (3A): 85-9
211. Lentz MJ, Landis CA, Rothermel J, et al. Effects of selective slow wave sleep disruption on musculoskeletal pain and fatigue in middle aged women. J Rheumatol 1999 Jul; 26 (7): 1586-92
212. Broughton R, Mamelak M. Gamma-hydroxybutyrate in the treatment of compound narcolepsy: a preliminary report: I. New York: Spectrum, 1976
213. Broughton R, Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate. Can J Neurol Sci 1979 Feb; 6 (1): 1-6
214. Mamelak M, Scharf MB, Woods M. Treatment of narcolepsy with gamma-hydroxybutyrate: a review of clinical and sleep laboratory findings. Sleep 1986; 9 (1 Pt 2): 285-9
215. Scharf MB, Brown D, Woods M, et al. The effects and effectiveness of gamma-hydroxybutyrate in patients with narcolepsy. J Clin Psychiatry 1985 Jun; 46 (6): 222-5
216. Scrima L, Hartman PG, Johnson Jr FH, et al. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures. Biol Psychiatry 1989 Aug; 26 (4): 331-43
217. Lammers GJ, Arends J, Declerck AC, et al. Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep 1993 Apr; 16 (3): 216-20
218. Scrima L, Hartman PG, Johnson Jr FH, et al. The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. Sleep 1990 Dec; 13 (6): 479-90
219. US Xyrem® Multicenter Study Group. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003 Feb 1; 26 (1): 31-5
220. The Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005; 1 (4): 289-95
221. Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006; 29 (7): 939-46